Differential Effects of the G118R, H51Y, and E138K Resistance Substitutions in Different Subtypes of HIV Integrase

Dolutegravir (DTG) is the latest antiretroviral (ARV) approved for the treatment of human immunodeficiency virus (HIV) infection. The G118R substitution, previously identified with MK-2048 and raltegravir, may represent the initial substitution in a dolutegravir resistance pathway. We have found tha...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Virol
Glavni autori: Quashie, Peter K., Oliviera, Maureen, Veres, Tamar, Osman, Nathan, Han, Ying-Shan, Hassounah, Said, Lie, Yolanda, Huang, Wei, Mesplède, Thibault, Wainberg, Mark A.
Format: Artigo
Jezik:Inglês
Izdano: American Society for Microbiology 2014
Teme:
Vaccines and Antiviral Agents
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4337543/
https://ncbi.nlm.nih.gov/pubmed/25552724
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.03353-14
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items